Vielight Neuro RX Gamma Alzheimer’s Pivotal Trial

The Neuro RX Gamma device delivers near infrared light to the brain via the head and the nose.

It is a simple and non-invasive home-based treatment.

This clinical trial is designed to evaluate the efficacy of the Neuro RX Gamma device in moderate to severe Alzheimer’s disease.

The trial will recruit 228 participants across 12 sites in North America. (Toronto, Ottawa, Vancouver, Florida)



We are looking for adults who:

  • have moderate to severe Alzheimer’s disease

  • are 50 years of age or older

  • have a dedicated caregiver

  • are not involved in another clinical trial

  • are not sensitive to light

What’s Involved?

Step 1
Screening visit

Informed consent, Imaging and Cognitive assessments

Step 2
Baseline visit

Cognitive assessments, device assignment and training

Step 3
Home treatment sessions

20 minutes with the Neuro RX Gamma, 6 days per week for 24 weeks

Step 4
Week 12 and 24 follow up visits

Cognitive assessments

Clinical Sites and Contacts


  • Sunnybrook Research Institute (Recruiting)
    2075 Bayview Avenue
    Toronto, Ontario,
    Canada, M4N 3M5
    Karan Patel
    416-480-6100 ext 83725
    [email protected]
    Principal Investigator: Sandra Black
  • Baycrest Hospital (Recruiting)
    3560 Bathurst Street
    Toronto, Ontario,
    Canada, M6A 2E1
    Naga Avvaru
    (416)-785-2500 ext 3627
    [email protected]
    Principal Investigator: Howard Chertkow
  • St. Michael’s Hospital (Recruiting)
    30 Bond St,
    Toronto, Ontario,
    Canada, M5B1W8
    Arthishia Shanmuganathan
    [email protected]
    Principal Investigator: Corinne Fischer, MD
  • Toronto Memory Program (Not Recruiting)
    1 Valleybrook Drive, Suite 400
    Toronto, Ontario, Canada, M3B2S7
    Contact: Clinical Trial Educator
  • Bruyère Research Institute (Recruiting)
    Ottawa, Ontario,
    Canada, K1R 6M1464
    Anna Voronchikhina, MA
    1-613-562-6262 ext 1278
    [email protected]
    Principal Investigator: Andrew Frank
  • Ottawa Memory Clinic (Recruiting)
    1600 Carling Avenue, Suite 100
    Ottawa, Ontario,
    Canada, K1Z 1G3
    Elitza Hristova
    613-702-1000 ext 415
    [email protected]
    Principal Investigator: Richard Bergeron

Okanagan Clinical Trials
Kelowna, British Columbia,
Canada, V1Y 1Z9
Carol Fazekas
[email protected]
Principal Investigator: Eugene Okorie

Healthtech Connex / Fraser Health
Unit 201, City Centre 1
13737 96th Avenue
Surrey, British Columbia,
Canada, V3V 0C6
Gabriela Pawlowski
[email protected]
Principal Investigator: George Medvedev, MD

True North Clinical Research Recruiting
36 Solutions Drive, Suite 440
Halifax, Nova Scotia,
Canada, B3S 1N2
Julie Thorsen
[email protected]
Principal Investigator: David Wilcox


Headlands Research
Orlando, Florida,
United States, 32819
Wesley Van Ever
[email protected]
Principal Investigator: Christopher Galloway

History of Research

  • Photobiomodulation for Improving Brain Function in Dementia
    [ Learn more ]
  • Pulsed Near Infrared Transcranial and Intranasal Photobiomodulation Significantly Modulates Neural Oscillations
    [ Learn more ]
  • Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report
    [ Learn more ]

Contact Us

Interested? Our research team will be happy to assist you.

Alternatively, fill out the form below to send us a message.

    Please answer the question below to submit form (required)